A detailed history of Westover Capital Advisors, LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Westover Capital Advisors, LLC holds 8,567 shares of AZN stock, worth $660,772. This represents 0.17% of its overall portfolio holdings.

Number of Shares
8,567
Previous 4,246 101.77%
Holding current value
$660,772
Previous $285,000 103.51%
% of portfolio
0.17%
Previous 0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$61.03 - $69.57 $263,710 - $300,611
4,321 Added 101.77%
8,567 $580,000
Q4 2023

Feb 06, 2024

SELL
$61.89 - $69.28 $928 - $1,039
-15 Reduced 0.35%
4,246 $285,000
Q3 2023

Nov 13, 2023

SELL
$64.85 - $71.7 $3,242 - $3,585
-50 Reduced 1.16%
4,261 $288,000
Q2 2023

Aug 11, 2023

SELL
$69.91 - $75.81 $1,188 - $1,288
-17 Reduced 0.39%
4,311 $308,000
Q4 2022

May 18, 2023

BUY
$54.21 - $70.44 $1,138 - $1,479
21 Added 0.49%
4,328 $293,000
Q3 2022

Nov 14, 2022

SELL
$53.02 - $135.75 $57,897 - $148,239
-1,092 Reduced 20.23%
4,307 $236,000
Q2 2022

Aug 12, 2022

BUY
$59.26 - $71.14 $319,944 - $384,084
5,399 New
5,399 $357,000
Q4 2021

Feb 14, 2022

SELL
$54.02 - $63.83 $268,965 - $317,809
-4,979 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$55.56 - $60.79 $12,556 - $13,738
226 Added 4.75%
4,979 $299,000
Q2 2021

Aug 10, 2021

SELL
$48.42 - $60.18 $6,391 - $7,943
-132 Reduced 2.7%
4,753 $285,000
Q1 2021

May 18, 2021

BUY
$47.16 - $54.44 $12,968 - $14,971
275 Added 5.97%
4,885 $243,000
Q4 2020

Feb 16, 2021

SELL
$48.52 - $58.02 $21,931 - $26,225
-452 Reduced 8.93%
4,610 $230,000
Q3 2020

Nov 19, 2020

BUY
$53.07 - $61.1 $23,987 - $27,617
452 Added 9.8%
5,062 $277,000
Q3 2019

Nov 12, 2019

BUY
$40.12 - $45.47 $184,953 - $209,616
4,610 New
4,610 $205,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $239B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Westover Capital Advisors, LLC Portfolio

Follow Westover Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Westover Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Westover Capital Advisors, LLC with notifications on news.